NovaBay Pharmaceuticals, Inc.
NBY
$1.44
-$0.09-5.88%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.83M | 4.74M | 7.12M | 9.75M | 9.56M |
| Total Other Revenue | -3.00K | 14.00K | 27.00K | 34.00K | 9.00K |
| Total Revenue | 2.83M | 4.75M | 7.15M | 9.78M | 9.57M |
| Cost of Revenue | 1.29M | 807.00K | 807.00K | 807.00K | 1.02M |
| Gross Profit | 1.54M | 1.50M | 1.50M | 1.50M | 1.08M |
| SG&A Expenses | 8.58M | 9.08M | 8.80M | 8.39M | 7.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.88M | 9.89M | 9.62M | 9.21M | 8.72M |
| Operating Income | -7.05M | -7.58M | -7.31M | -6.90M | -6.62M |
| Income Before Tax | -7.95M | -8.47M | -8.66M | -8.25M | -8.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.95 | -8.47 | -8.66 | -8.25 | -8.65 |
| Earnings from Discontinued Operations | 11.19M | 11.80M | 12.32M | 1.03M | -1.47M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.24M | 3.32M | 3.66M | -7.22M | -10.12M |
| EBIT | -7.05M | -7.58M | -7.31M | -6.90M | -6.62M |
| EBITDA | -7.04M | -7.57M | -7.29M | -6.87M | -6.58M |
| EPS Basic | 3.71 | -4.78 | -9.99 | -166.97 | -398.86 |
| Normalized Basic EPS | -3.85 | -8.17 | -12.70 | -88.95 | -115.70 |
| EPS Diluted | 3.69 | -4.82 | -10.02 | -166.99 | -398.88 |
| Normalized Diluted EPS | -3.82 | -8.13 | -12.67 | -88.95 | -115.70 |
| Average Basic Shares Outstanding | 5.00M | 4.06M | 3.12M | 2.09M | 525.40K |
| Average Diluted Shares Outstanding | 5.02M | 4.08M | 3.14M | 2.09M | 525.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 148.47% | -- | -- | -- | -- |